Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195

Diabetologia

Volumn 42, Issue 5, 1999, Pages 579-588

  Tsuchida, K ^a   Makita, Z ^a   Yamagishi, S ^b   Atsumi, T ^a   Miyoshi, H ^a   Obara, S ^a   Ishida, M ^a   Ishikawa, S ^c   Yasumura, K ^c   Koike, T ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c Fujii Memorial Research Institute   (Japan)

Author keywords

Extracellular matrix; Glomerulosclerosis; Otsuka Long Evans Tokushima Fatty rat; Type II diabetes mellitus; Type IV collagen

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; ADVANCED GLYCATION END PRODUCT; COLLAGEN TYPE 4; MESSENGER RNA; THIAZOLIDINE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; IMMUNOHISTOCHEMISTRY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NORTHERN BLOTTING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; BLOOD GLUCOSE; COLLAGEN; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENDOTHELIAL GROWTH FACTORS; GENE EXPRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; KIDNEY; KIDNEY GLOMERULUS; LYMPHOKINES; MALE; RATS; RATS, INBRED OLETF; RNA, MESSENGER; THIADIAZOLES; THIAZOLIDINES; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033007062     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051198     Document Type: Article

References (59)

1. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC (1984) Structural-functional relationships in diabetic nephropathy. J Clin Invest 74: 1143-1155
2. Steffes MW, Bilous RW, Sutherland DE, Mauer SM (1992) Cell and matrix components of the glomerular mesangium in type I diabetes. Diabetes 41: 679-684
3. Ziyadeh FN (1993) The extracellular matrix in diabetic nephropathy. Am J Kidney Dis 22: 736-744
4. Lane PH, Steffes MW, Mauer SM (1990) Renal histologic changes in diabetes mellitus. Semin Nephrol 10: 254-259
5. Cohen MP, Ziyadeh FN (1996) Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy. J Am Soc Nephrol [editorial] 7: 183-190
6. Vlassara H (1994) Recent progress on the biologic and clinical significance of advanced glycosylation end products. J Lab Clin Med 124: 19-30
7. Vlassara H (1997) Recent progress in advanced glycation end products and diabetic complications. Diabetes 46: S19-S25
8. Vlassara H, Bucala R, Striker L (1994) Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70: 138-151
9. Makita Z, Bucala R, Rayfield EJ et al. (1994) Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343: 1519-1522
10. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M (1994) Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 91: 11704-11708
11. Makita Z, Radoff S, Rayfield EJ et al. (1991) Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325: 836-842
12. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G (1991) Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40: 1328-1334
13. Yang CW, Vlassara H, Striker GE, Striker LJ (1995) Administration of AGEs in vivo induces genes implicated in diabetic glomerulosclerosis. Kidney Int [Suppl] 49: S55-S58
14. Makita Z, Vlassara H, Rayfield E et al. (1992) Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 258: 651-653
15. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ (1994) Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 91: 9436-9440
16. Vlassara H, Brownlee M, Cerami A (1986) Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors. J Exp Med 164: 1301-1309
17. Esposito C, Gerlach H, Brett J, Stern D, Vlassara H (1989) Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 170: 1387-1407
18. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H (1991) Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 174: 931-939
19. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ (1992) Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci USA 89: 2873-2877
20. Steffes MW, Osterby R, Chavers B, Mauer SM (1989) Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 38: 1077-1081
21. Border WA, Yamamoto T, Noble NA (1996) Transforming growth factor beta in diabetic nephropathy. Diabetes Metab Rev 12: 309-339
22. Sharma K, Ziyadeh FN (1995) Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 44: 1139-1146
23. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232: 1629-1632
24. Edelstein D, Brownlee M (1992) Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 41: 26-29
25. Hammes HP, Strodter D, Weiss A, Bretzel RG, Federlin K, Brownlee M (1995) Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. Diabetologia 38: 656-660
26. Soulis T, Cooper ME, Vranes D, Bucala R, Jerums G (1996) Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int 50: 627-634
27. Nathan DM (1995) Prevention of long-term complications of non-insulin-dependent diabetes mellitus. Clin Invest Med 18: 332-339
28. Striker LJ, Striker GE (1996) Administration of AGEs in vivo induces extracellular matrix gene expression. Nephrol Dial Transplant 11: 62-65
29. Nakamura S, Makita Z, Ishikawa S et al. (1997) Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46: 895-899
30. Sarzani R, Brecher P, Chobanian AV (1989) Growth factor expression in aorta of normotensive and hypertensive rats. J Clin Invest 83: 1404-1408
31. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA (1993) Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90: 1814-1818
32. Ignotz RA, Massague J (1986) Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 261: 4337-4345
33. Bassols A, Massague J (1988) Transforming growth factor beta regulates the expression and structure of extracellular matrix chondroitin/dermatan sulfate proteoglycans. J Biol Chem 263: 3039-3045
34. Edwards DR, Murphy G, Reynolds JJ et al. (1987) Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 6: 1899-1904
35. Laiho M, Saksela O, Keski-Oja J (1987) Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor Pericellular deposition and sensitivity to exogenous urokinase. J Biol Chem 262: 17467-17474
36. Ignotz RA, Massague J (1987) Cell adhesion protein receptors as targets for transforming growth factor-beta action. Cell 51: 189-197
37. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985
38. Brown LF, Berse B, Tognazzi K et al. (1992) Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 42: 1457-1461
39. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR (1992) Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in norman tissues, macrophages, and tumors. Mol Biol Cell 3: 211-220
40. Iijima K, Yoshikawa N, Connolly DT, Nakamura H (1993) Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney Int 44: 959-966
41. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T (1992) Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 41: 1422-1428
42. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159
43. Rocco MV, Neilson EG, Hoyer JR, Ziyadeh FN (1992) Attenuated expression of epithelial cell adhesion molecules in murine polycystic kidney disease. Am J Physiol 262: F679-F686
44. Conn G, Bayne ML, Soderman DD et al. (1990) Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci USA 87: 2628-2632
45. Park IS, Kiyomoto H, Abboud SL, Abboud HE (1997) Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes. Diabetes 46: 473-480
46. Yokoyama H, Deckert T (1996) Central role of TGF-beta in the pathogenesis of diabetic nephropathy and macrovascular complications: a hypothesis. Diabet Med 13: 313-320
47. Ziyadeh FN (1994) Role of transforming growth factor beta in diabetic nephropathy. Exp Nephrol 2: 137
48. Kim SJ, Denhez F, Kim KY, Holt JT, Sporn MB, Roberts AB (1989) Activation of the second promoter of the transforming growth factor-beta 1 gene by transforming growth factor-beta 1 and phorbol ester occurs through the same target sequences. J Biol Chem 264: 19373-19378
49. Sharma K, Jin Y, Guo J, Ziyadeh FN (1996) Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45: 522-530
50. Rumble JR, Cooper ME, Soulis T et al. (1997) Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products. J Clin Invest 99: 1016-1027
51. Aiello LP, Avery RL, Arrigg PG et al. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487
52. Thieme H, Aiello LP, Takagi H, Ferrara N, King GL (1995) Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes 44: 98-103
53. Iruela-Arispe L, Gordon K, Hugo C et al. (1995) Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am J Pathol 147: 1715-1727
54. Brenner BM (1983) Hemodynamically mediated glomerular injury and the progressive nature of kidney disease [clinical conference]. Kidney Int 23: 647-655
55. Seyer-Hansen K (1983) Renal hypertrophy in experimental diabetes mellitus. Kidney Int 23: 643-646
56. Nyengaard JR, Bendtsen TF (1993) The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes. Diabetologia 36: 189-194
57. Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039
58. Pertovaara L, Kaipainen A, Mustonen T et al. (1994) Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 269: 6271-6274
59. Mandriota SJ, Menoud PA, Pepper MS (1996) Transforming growth factor beta 1 down-regulates vascular endothelial growth factor receptor 2/flk-1 expression in vascular endothelial cells. J Biol Chem 271: 11500-11505